KPV

Fragment Logic: KPV Against Its Parent

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Alpha-MSH has two functionally separable activities: pigmentation and anti-inflammation. Isolating the C-terminal tripeptide keeps the second without the first, which is the entire rationale for KPV existing as a distinct research compound.

Key facts

Parent
alpha-MSH, 13 residues, 1,664.9 Da
Fragment
KPV, 3 residues, 342.43 Da
Discarded
Melanocortin receptor engagement
Retained
Reported anti-inflammatory activity
Additional change
Size permits intracellular access
Guaranteed?
No, fragments are different molecules

The clean case for a fragment

Fragment isolation is most defensible when a parent has two separable functions and only one is wanted. Alpha-MSH is close to that ideal: pigmentation runs through melanocortin receptor engagement by the core sequence, and anti-inflammatory activity localises to the C-terminus. Taking the C-terminus alone is a targeted separation rather than a hopeful truncation.

What changes beyond losing a function

Size, dramatically. Going from 1,665 Da to 342 Da is not a minor trim. It is a fivefold reduction that changes what the molecule can physically do. The parent cannot cross membranes; the fragment plausibly can. So the fragment is not simply the parent minus pigmentation; it is a molecule with different access to different compartments.

Research material referenced

KPV 10mg, third-party HPLC tested

Buy KPV · £28.99

Why that cuts both ways

A fragment small enough to enter cells might act by a mechanism the parent never used, which would mean the anti-inflammatory activity of KPV and of alpha-MSH are not necessarily the same phenomenon. That possibility is rarely acknowledged, and it means parent-fragment read-across should be applied cautiously in both directions.

How this compares with the library's other fragments

The 7-residue LKKTETQ fragment that some papers call TB-500 takes an internal motif from thymosin beta-4, while most findings cited under the TB-500 name used the full protein. Modified GRF (1-29) takes GHRH's active fragment and retains full agonist activity. KPV sits between: the separation is well motivated, and the size change is large enough that the fragment is a different kind of molecule from its parent.

What the delivery work implies

The 2017 Molecular Therapy paper on targeted oral delivery indicates that reaching the intended tissue was the practical obstacle, not activity. A compound needing a delivery vehicle is one whose free form does not arrive where it is wanted. That is a real limitation, and one the fragment inherited from being very small and rapidly cleared.

Frequently asked questions

Why not just use alpha-MSH?

It drives pigmentation through melanocortin receptors, which is a confound for anti-inflammatory research. The fragment separates the two activities.

Does KPV work the same way as its parent?

Not necessarily. At a fifth of the mass it may access compartments alpha-MSH cannot, so the mechanisms may differ.

What limits KPV in practice?

Delivery. The published targeted-delivery work indicates the free tripeptide's arrival at intended tissue was the obstacle.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KPV articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.